Class Actions Allege VistaGen Therapeutics Misled Investors Over PALISADE‑2 Fasedienol Results

Fasedienol Trial Dispute Drives Litigation Against VistaGen Therapeutics

A pair of securities firms files class actions accusing VistaGen Therapeutics of misleading investors about the results and prospects of its fasedienol program, centring on the PALISADE‑2 trial. The Schall Law Firm and DJS Law Group allege the company violates Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b‑5 by making public statements from April 1, 2024 through December 16, 2025 that presented an overly optimistic view of Phase 3 prospects. Both complaints contend that disclosures describing PALISADE‑2 as positive and suggesting a high likelihood of Phase 3 success are false and materially misleading.

The firms say VistaGen downplays the risk of clinical failure and creates a misleading narrative about fasedienol’s efficacy, which they assert inflated market expectations and left investors exposed when the facts differ from company statements. The complaints seek to recover losses for shareholders who purchased VistaGen securities during the class period and to hold the company accountable for the allegedly inaccurate public representations about clinical data and program trajectory. The litigation frames the dispute as one about the adequacy and timeliness of clinical disclosures rather than the underlying science itself.

The lawsuits highlight the legal pathway available to investors where companies communicate clinical results and future prospects, underscoring tensions between biopharmaceutical disclosure practices and securities laws. Neither class is certified yet, and plaintiffs must still prove the claims through discovery and possible motion practice; remedies and damages remain to be determined by the courts. The firms emphasize that potential plaintiffs must act promptly to preserve statutory deadlines and to consider lead plaintiff appointments where applicable.

Preservation of Claims and Deadlines

Both firms set a March 16, 2026 deadline for investors who purchased VistaGen securities during the class period to contact counsel to preserve potential claims. They note that absent timely action, investors risk forfeiting recovery opportunities and that lead plaintiff appointments may affect the course of the litigation.

Law Firms’ Positions and Contact Paths

The Schall Law Firm and DJS Law Group describe their practices as focused on securities class actions and shareholder litigation and invite affected shareholders to review complaint materials. Each firm provides contact information for no‑cost consultations and cautions that the announcements may constitute attorney advertising in some jurisdictions.